 Proto-Oncogene Proteins
"Proto-Oncogene Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
| Descriptor ID |
D011518
|
| MeSH Number(s) |
D12.776.624.664.700
|
| Concept/Terms |
Proto-Oncogene Proteins- Proto-Oncogene Proteins
- Proto Oncogene Proteins
- Proto-Oncogene Products, Cellular
- Cellular Proto-Oncogene Products
- Proto Oncogene Products, Cellular
- Proto Oncogene Proteins, Cellular
- c-onc Proteins
- c onc Proteins
- Cellular Proto-Oncogene Proteins
- Cellular Proto Oncogene Proteins
- Proto-Oncogene Proteins, Cellular
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins".
This graph shows the total number of publications written about "Proto-Oncogene Proteins" by people in this website by year, and whether "Proto-Oncogene Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 6 | 5 | 11 | | 1996 | 5 | 6 | 11 | | 1997 | 11 | 4 | 15 | | 1998 | 1 | 1 | 2 | | 1999 | 4 | 3 | 7 | | 2000 | 14 | 3 | 17 | | 2001 | 6 | 3 | 9 | | 2002 | 7 | 8 | 15 | | 2003 | 7 | 9 | 16 | | 2004 | 14 | 17 | 31 | | 2005 | 6 | 9 | 15 | | 2006 | 9 | 4 | 13 | | 2007 | 4 | 2 | 6 | | 2008 | 7 | 6 | 13 | | 2009 | 11 | 3 | 14 | | 2010 | 6 | 8 | 14 | | 2011 | 9 | 7 | 16 | | 2012 | 9 | 8 | 17 | | 2013 | 14 | 9 | 23 | | 2014 | 8 | 9 | 17 | | 2015 | 6 | 4 | 10 | | 2016 | 7 | 3 | 10 | | 2017 | 5 | 3 | 8 | | 2018 | 11 | 7 | 18 | | 2019 | 6 | 2 | 8 | | 2020 | 3 | 5 | 8 | | 2021 | 5 | 3 | 8 | | 2022 | 0 | 7 | 7 | | 2023 | 1 | 4 | 5 | | 2024 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins" by people in Profiles.
-
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024 01 11; 390(2):118-131.
-
Chen N, Tyler LC, Le AT, Welsh EA, Fang B, Elliott A, Davies KD, Danhorn T, Riely GJ, Ladanyi M, Haura EB, Doebele RC. MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling. Mol Cancer Ther. 2024 Jan 03; 23(1):92-105.
-
Liao Y, Remsing Rix LL, Li X, Fang B, Izumi V, Welsh EA, Monastyrskyi A, Haura EB, Koomen JM, Doebele RC, Rix U. Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2. Cell Chem Biol. 2024 Feb 15; 31(2):284-297.e10.
-
Peters TL, Chen N, Tyler LC, Le AT, Dimou A, Doebele RC. Intrinsic resistance to ROS1 inhibition in a patient with CD74-ROS1 mediated by AXL overexpression. Thorac Cancer. 2023 Nov; 14(33):3259-3265.
-
Ravindran Menon D, Hammerlindl H, Gimenez G, Hammerlindl S, Zuegner E, Torrano J, Bordag N, Emran AA, Giam M, Denil S, Pavelka N, Tan AC, Sturm RA, Haass NK, Rancati G, Herlyn M, Magnes C, Eccles MR, Fujita M, Schaider H. H3K4me3 remodeling induced acquired resistance through O-GlcNAc transferase. Drug Resist Updat. 2023 Nov; 71:100993.
-
Szwarc MM, Guarnieri AL, Joshi M, Duc HN, Laird MC, Pandey A, Khanal S, Dohm E, Bui AK, Sullivan KD, Galbraith MD, Andrysik Z, Espinosa JM. FAM193A is a positive regulator of p53 activity. Cell Rep. 2023 03 28; 42(3):112230.
-
Drilon A, Horan JC, Tangpeerachaikul A, Besse B, Ou SI, Gadgeel SM, Camidge DR, van der Wekken AJ, Nguyen-Phuong L, Acker A, Keddy C, Nicholson KS, Yoda S, Mente S, Sun Y, Soglia JR, Kohl NE, Porter JR, Shair MD, Zhu V, Davare MA, Hata AN, Pelish HE, Lin JJ. NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer Discov. 2023 03 01; 13(3):598-615.
-
Langston J, Patil T, Ross Camidge D, Bunn PA, Schenk EL, Pacheco JM, Jurica J, Waxweiler TV, Kavanagh BD, Rusthoven CG. CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer. Lung Cancer. 2023 04; 178:103-107.
-
Gilani A, Siddiq Z, Kissell E, Kasson J, Kleinschmidt-DeMasters BK. Genomic and epigenomic re-categorization of congenital glioblastoma and desmoplastic infantile ganglioglioma. Childs Nerv Syst. 2023 07; 39(7):1861-1868.
-
Pietras EM, DeGregori J. Dangerous Liaisons between Tet2 Mutation, Inflammatory Monocytes, and Leukemogenesis. Cancer Discov. 2022 10 05; 12(10):2234-2236.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|